A Randomized, Two-Period, Double-Blind Placebo-Controlled and Open-Label, Multicenter Extension Study to Determine the Long-Term Safety and Tolerability of JNJ-54861911 in Subjects in the Early Alzheimer's Disease Spectrum

Trial Profile

A Randomized, Two-Period, Double-Blind Placebo-Controlled and Open-Label, Multicenter Extension Study to Determine the Long-Term Safety and Tolerability of JNJ-54861911 in Subjects in the Early Alzheimer's Disease Spectrum

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 18 Sep 2017

At a glance

  • Drugs JNJ 54861911 (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 24 Nov 2016 Status changed from recruiting to active, no longer recruiting.
    • 05 Sep 2016 Planned End Date changed from 1 Jun 2024 to 1 Oct 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top